Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 12:42 am EST
Share
Ildong Holdings Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 4,468.47 million compared to KRW 4,305.33 million a year ago. Net loss was KRW 25,552.84 million compared to KRW 11,863.12 million a year ago. Basic loss per share from continuing operations was KRW 2,263 compared to KRW 1,051 a year ago. Diluted loss per share from continuing operations was KRW 2,263 compared to KRW 1,051 a year ago. Basic loss per share was KRW 2,263 compared to KRW 1,051 a year ago.
For the nine months, sales was KRW 12,150.77 million compared to KRW 14,825.04 million a year ago. Net loss was KRW 48,510.76 million compared to KRW 54,924.12 million a year ago. Basic loss per share from continuing operations was KRW 4,296 compared to KRW 4,864 a year ago. Diluted loss per share from continuing operations was KRW 4,296 compared to KRW 4,864 a year ago. Basic loss per share was KRW 4,296 compared to KRW 4,864 a year ago.
Ildong Holdings Co., Ltd., formerly Ildong Pharmaceuticals Co., Ltd., is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. It also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.
ILDONG HOLDINGS CO., LTD. 
